Disease · MONDO_0026045
prurigo nodularis
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. prurigo nodularis. Diseases, record MONDO_0026045. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0026045
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- prurigo nodularis
- Open Targets ID
- MONDO_0026045
- Highest stage of its drugs
- Approval, for 1 of its 19 drugs, from PMDA
Source Open Targets
Drugs19
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| NEMOLIZUMAB | CHEMBL4297794 | Antibody | Approval | PMDA | 6 | 5 | 5 | Drugs and targets |
| DUPILUMAB | CHEMBL2108675 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| POVORCITINIB | CHEMBL5095079 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| RUXOLITINIB | CHEMBL1789941 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| SERLOPITANT | CHEMBL447955 | Small molecule | Phase 3 | ClinicalTrials.gov and TTD | 3 | 2 | 2 | Drugs and targets |
| ROCATINLIMAB | CHEMBL4594567 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| STAPOKIBART | CHEMBL5095324 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NALBUPHINE | CHEMBL895 | Small molecule | Phase 2/3 | ClinicalTrials.gov and TTD | 4 | 3 | 3 | Drugs and targets |
| BARZOLVOLIMAB | CHEMBL5095266 | Antibody | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ABROCITINIB | CHEMBL3655081 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 19
See all 19 drugsTargets19
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| JAK1 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor | Phase 3 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor | Phase 3 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| JAK3 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor | Phase 3 | https://conductscience.org/library/genes/3718 | Drugs and targets |
| OPRD1 | Opioid receptors; mu/kappa/delta | 2 | Opioid receptors; mu/kappa/delta agonist | Phase 2/3 | https://conductscience.org/library/genes/4985 | Drugs and targets |
| OPRK1 | Opioid receptors; mu/kappa/delta | 2 | Opioid receptors; mu/kappa/delta agonist | Phase 2/3 | https://conductscience.org/library/genes/4986 | Drugs and targets |
| OPRM1 | Opioid receptors; mu/kappa/delta | 2 | Opioid receptors; mu/kappa/delta agonist | Phase 2/3 | https://conductscience.org/library/genes/4988 | Drugs and targets |
| TYK2 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor | Phase 3 | https://conductscience.org/library/genes/7297 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Phase 2 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| IL31RA | Interleukin-31 receptor subunit alpha | 1 | Interleukin-31 receptor subunit alpha inhibitor | Approval | https://conductscience.org/library/genes/133396 | Drugs and targets |
| IL4R | Interleukin-4 receptor subunit alpha | 1 | Interleukin-4 receptor subunit alpha antagonist | Phase 3 | https://conductscience.org/library/genes/3566 | Drugs and targets |
1 to 10 of 19
See all 19 targetsTrials33
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03677401 | Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis | Phase 3 | 295 | 2020-10-28 | Pruritus, Prurigo Nodularis | SERLOPITANT | Its record names the disease | ClinicalTrials.gov |
| NCT04501666 | Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) | Phase 3 | 286 | 2024-07-10 | Prurigo Nodularis | NEMOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04501679 | A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) | Phase 3 | 274 | 2024-07-10 | Prurigo Nodularis | NEMOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03816891 | Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis | Phase 2 | 240 | 2026-01-13 | Prurigo Nodularis, Pruritis | VIXARELIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05755438 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) | Phase 3 | 204 | 2025-11-14 | Prurigo | RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT05764161 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) | Phase 3 | 190 | 2025-11-24 | Prurigo Nodularis | RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04202679 | Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2) | Phase 3 | 160 | 2022-09-28 | Neurodermatitis | DUPILUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04183335 | Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME) | Phase 3 | 151 | 2022-12-12 | Neurodermatitis | DUPILUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05061693 | A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | Phase 2 | 146 | 2024-08-27 | Prurigo Nodularis | POVORCITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02196324 | A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN) | Phase 2 | 128 | 2021-02-02 | Prurigo Nodularis | SERLOPITANT | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 33
See all 33 trialsComparisons in its trials45
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Serlopitant 5 mg vs Placebo: deaths from any cause | 1 of 147 | 0 of 148 | 295 | NCT03677401 | Trial comparisons |
| Serlopitant 5 mg vs Placebo: serious adverse events | 5 of 147 | 2 of 148 | 295 | NCT03677401 | Trial comparisons |
| Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID: deaths from any cause | 0 of 184 | 0 of 103 | 287 | NCT05755438 | Trial comparisons |
| Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID: serious adverse events | 13 of 184 | 5 of 103 | 287 | NCT05755438 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With an Improvement of >=4 From Baseline in Sleep Disturbance Numeric Rating Scale (SD NRS) at Week 16 | 95 of 190 | 11 of 96 | 286 | NCT04501666 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With PP NRS < 2 at Week 4 | 41 of 190 | 1 of 96 | 286 | NCT04501666 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With an Improvement of Greater Than or Equal to (>=) 4 From Baseline in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16 | 111 of 190 | 16 of 96 | 286 | NCT04501666 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With an Improvement of >= 4 From Baseline in Weekly Average PP NRS at Week 4 | 78 of 190 | 6 of 96 | 286 | NCT04501666 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With an Improvement of >=4 From Baseline in SD NRS at Week 4 | 59 of 190 | 5 of 96 | 286 | NCT04501666 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With PP NRS < 2 at Week 16 | 65 of 190 | 4 of 96 | 286 | NCT04501666 | Trial comparisons |
1 to 10 of 45
See all 45 comparisons in its trialsPapers from its trials20
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 37888917 | RESULT | 2 | PubMed |
| 42120670 | DERIVED | 2 | PubMed |
| 41922877 | DERIVED | 2 | PubMed |
| 41405882 | DERIVED | 1 | PubMed |
| 41405008 | DERIVED | 1 | PubMed |
| 41272364 | DERIVED | 1 | PubMed |
| 41219577 | DERIVED | 2 | PubMed |
| 41051123 | DERIVED | 1 | PubMed |
| 40266487 | DERIVED | 2 | PubMed |
| 39602139 | DERIVED | 1 | PubMed |
1 to 10 of 20
See all 20 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0026045
GET https://conductscience.org/api/diseases/v1/MONDO_0026045/trials?page=2